 Use of new oral anticoagulants NOAC in patients before and after radiofrequency ablation with pulmonary vein isolation PVI is still controversial. Experience is reported from consecutive patients ablated with PVI for atrial fibrillation and treated with dabigatran, rivaroxaban, or apixaban from Nov 2011 until Dec 2014. Patients paused their NOAC treatment for 24 hours before ablation. Patients were routinely followed up after 3 months with a standard formular focused on possible adverse events major bleeding complications or thromboembolic events to NOAC treatment. Adverse events related to the use of NOAC were registered during treatment or during 3 months of follow-up. 